NASDAQ: RGENRepligen Corp Stock Ownership - Who owns Repligen?
Insider buying vs selling
Have Repligen Corp insiders been buying or selling?
Buy
Sell
| Name | Role | Date | Shares | Price | Value |
|---|---|---|---|---|---|
| Jason K. Garland | CFO | 2026-06-25 | 733 | $145.00 | $106.29kSell |
| Brian Robb Douglass | CHIEF PRODUCT OFFICER | 2026-05-07 | 334 | $126.43 | $42.23kSell |
| Glenn P. Muir | Director | 2026-05-07 | 2,434 | $38.76 | $94.34kBuy |
| Olivier Loeillot | Chief Executive Officer | 2026-04-21 | 3,832 | $140.00 | $536.48kSell |
| James Bylund | Chief Operating Officer | 2026-03-04 | 62 | $125.84 | $7.80kSell |
| Ralf Kuriyel | Senior VP RD | 2026-03-04 | 42 | $125.84 | $5.29kSell |
| Brian Robb Douglass | CHIEF PRODUCT OFFICER | 2026-03-02 | 221 | $124.97 | $27.62kSell |
| James Bylund | Chief Operating Officer | 2026-03-02 | 2,433 | $124.97 | $304.05kSell |
| Jason K. Garland | CFO | 2026-03-02 | 715 | $124.97 | $89.35kSell |
| Anthony Hunt | Director | 2026-03-02 | 9,897 | $124.97 | $1.24MSell |
RGEN insiders have sold more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership
Be the first to know when RGEN insiders and whales buy or sell their stock.
RGEN Shareholders
What type of owners hold Repligen Corp stock?
Institutional
Insider
Retail
| Name | Hold | Shares | Value | Type |
|---|---|---|---|---|
| Bvf Partners L P | 19.61% | 11,060,200 | $1.63B | Insider |
| Roy T. Eddleman | 13.63% | 7,685,810 | $1.13B | Insider |
| Blackrock Inc | 10.62% | 5,993,054 | $881.04M | Institution |
| Price T Rowe Associates Inc | 8.65% | 4,878,141 | $717.14M | Institution |
| Fmr LLC | 5.12% | 2,886,786 | $424.39M | Institution |
| United Capital Financial Advisors LLC | 4.92% | 2,773,980 | $407.80M | Institution |
| Vanguard Capital Management LLC | 4.25% | 2,396,511 | $352.31M | Institution |
| Vanguard Portfolio Management LLC | 4.09% | 2,305,094 | $338.87M | Institution |
| State Street Corp | 3.15% | 1,777,285 | $261.28M | Institution |
| Bank Of New York Mellon Corp | 2.71% | 1,531,402 | $225.13M | Institution |
RGEN vs Medical Stocks
Repligen Stock Ownership FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.